These findings demonstrate that manipulating Smaug activity protects against the effects of the DM1 mutation, and they also support the idea that restoring normal CUGBP1 function is a potential therapeutic approach. The gene discussed is SAMD4A; the disease is myotonic dystrophy type 1.